Equities analysts predict that Zoetis Inc. (NYSE:ZTS) will announce earnings per share (EPS) of $0.63 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Zoetis’ earnings, with estimates ranging from $0.62 to $0.64. Zoetis reported earnings of $0.52 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 21.2%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, November 1st.

On average, analysts expect that Zoetis will report full year earnings of $2.34 per share for the current financial year, with EPS estimates ranging from $2.30 to $2.37. For the next fiscal year, analysts anticipate that the firm will report earnings of $2.68 per share, with EPS estimates ranging from $2.59 to $2.74. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Zoetis.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter in the prior year, the company posted $0.49 earnings per share. The firm’s revenue was up 5.0% on a year-over-year basis.

A number of analysts have recently commented on the company. Cowen and Company set a $70.00 target price on Zoetis and gave the stock a “buy” rating in a research note on Monday, July 17th. BMO Capital Markets downgraded Zoetis from an “outperform” rating to a “market perform” rating and upped their target price for the stock from $64.00 to $65.00 in a research note on Tuesday, June 13th. They noted that the move was a valuation call. Cantor Fitzgerald set a $75.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Monday, August 14th. CL King began coverage on Zoetis in a research report on Friday, May 26th. They set a “buy” rating and a $71.00 price target on the stock. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price target on shares of Zoetis in a research report on Friday, July 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $65.44.

TRADEMARK VIOLATION WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/09/0-63-eps-expected-for-zoetis-inc-zts-this-quarter.html.

Zoetis (ZTS) traded down 0.23% during trading on Friday, reaching $64.70. 2,608,157 shares of the company were exchanged. The firm’s 50 day moving average price is $61.87 and its 200-day moving average price is $58.97. The stock has a market capitalization of $31.65 billion, a price-to-earnings ratio of 36.57 and a beta of 1.02. Zoetis has a one year low of $46.86 and a one year high of $65.12.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Gladstone Capital Management LLP purchased a new position in Zoetis in the second quarter valued at $3,134,000. Swiss National Bank boosted its holdings in Zoetis by 8.1% in the second quarter. Swiss National Bank now owns 1,796,380 shares of the company’s stock valued at $112,058,000 after purchasing an additional 133,900 shares during the period. Harbour Capital Advisors LLC boosted its holdings in Zoetis by 19.8% in the first quarter. Harbour Capital Advisors LLC now owns 20,005 shares of the company’s stock valued at $1,068,000 after purchasing an additional 3,300 shares during the period. Hermes Investment Management Ltd. boosted its holdings in Zoetis by 80.3% in the second quarter. Hermes Investment Management Ltd. now owns 236,350 shares of the company’s stock valued at $14,744,000 after purchasing an additional 105,276 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in Zoetis by 8.2% in the second quarter. Wells Fargo & Company MN now owns 5,113,948 shares of the company’s stock valued at $319,008,000 after purchasing an additional 389,260 shares during the period. Institutional investors and hedge funds own 93.31% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.